{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:45:47Z","timestamp":1785908747077,"version":"3.56.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Predictive biomarkers for patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) remain limited. Systemic inflammation plays a crucial role in cancer progression and immune regulation. We evaluated whether baseline 18F-FDG PET\/CT metabolic parameters and systemic inflammatory markers are associated with treatment response and survival in patients with advanced NSCLC treated with first-line ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Among 142 patients treated with first-line ICIs either as monotherapy or combined with chemotherapy, between October 2018 and December 2023, 116 had baseline PET\/CT imaging. Quantitative analyses of standardized uptake value max (SUVmax) and metabolic tumor volume (MTV) were restricted to 71 patients whose scans were performed at our institution. Associations with response, progression free survival (PFS), and overall survival (OS) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In multivariable models including clinical variables, PET biomarkers and inflammatory markers, no individual PET or inflammatory biomarker remained independently associated with survival. Combined models suggested better prognostic discrimination compared with PET-only or inflammation-only models (OS C-index 0.745; PFS C-index 0.750). In contrast, sex, TTF-1 status, and the presence of adrenal and lung metastases emerged as independent predictors of OS and\/or PFS. SUVmax correlated significantly with baseline CRP levels, while no significant associations were observed with LDH or NLR. MTV was associated with LDH but not with CRP or NLR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline PET-derived metabolic parameters and systemic inflammatory biomarkers may provide complementary prognostic information in advanced NSCLC treated with first-line ICIs. Integrated clinical, metabolic, and inflammatory models showed improved prognostic performance, supporting further prospective validation of multimodal risk stratification strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1837219","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:53:38Z","timestamp":1785905618000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline 18F-FDG PET\/CT metabolic parameters and systemic inflammatory markers in advanced NSCLC treated with first-line immunotherapy: an exploratory retrospective analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Blerina","family":"Resuli","sequence":"first","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), and Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), and Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"V\u00f6lter","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Kauffmann-Guerrero","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dahlmann","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Hirner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Unterrainer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Mertsch","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), and Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), and Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Mras","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), and Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Leuschner","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), and Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"R\u00fcbenthaler","sequence":"additional","affiliation":[{"name":"Department of Radiology, LMU University Hospital","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ludwig-Maximilian-University (LMU) University Hospital Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), and Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital of Munich","place":["Munich, Germany"]},{"name":"Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), and Bavarian Cancer Research Center (BZKF)","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"6","author":"Chen","year":"2014","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020349","article-title":"Intratumor heterogeneity in early lung adenocarcinoma","volume":"12","author":"Senosain","year":"2020","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1\u2013positive, advanced non-small-cell lung cancer (KEYNOTE-010)","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2903-7","article-title":"Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis","volume":"42","author":"Im","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.01.024","article-title":"Metabolic tumor burden as marker of outcome in advanced NSCLC","volume":"94","author":"Winther-Larsen","year":"2016","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/RLU.0000000000001886","article-title":"Baseline 18F-FDG PET\/CT metabolic parameters as prognostic markers in NSCLC","volume":"43","author":"Sharma","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.13.11456","article-title":"FDG PET\/CT parameters as prognostic indicators in lung cancer","volume":"202","author":"Sridhar","year":"2014","journal-title":"Am J Roentgenol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3747\/co.v17i4.567","article-title":"The predictive value of pre-treatment inflammatory markers in advanced NSCLC","volume":"17","author":"Kasymjanova","year":"2010","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","article-title":"The lung cancer immune microenvironment","volume":"19","author":"Altorki","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immunotherapy response","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden and outcome with ICIs","volume":"47","author":"Seban","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00259-019-04411-7","article-title":"FDG PET metrics as biomarkers in immunotherapy","volume":"135","author":"Seban","year":"2019","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07453-2","article-title":"Predicting PD-L1 expression status in NSCLC using radiomic analysis of 18F-FDG PET\/CT images","volume":"53","author":"Kiss","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/RLU.0000000000001886","article-title":"FDG PET\/CT and tumor microenvironment interactions","volume":"43","author":"Sharma","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133315","article-title":"Correlation of metabolic activity and immune infiltration in NSCLC","volume":"13","author":"Lopci","year":"2021","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15212754","article-title":"The role of 18F-FDG PET\/CT in monitoring immunotherapy response in non-small cell lung cancer","volume":"15","author":"Mladin","year":"2025","journal-title":"Diagnostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06794-8","article-title":"18F-FDG PET\/CT atypical response patterns to immunotherapy in NSCLC patients: long-term prognosis assessment and clinical management","volume":"51","author":"Masse","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020356","article-title":"Tumor burden measured by FDG PET and outcome of immunotherapy","volume":"12","author":"Kitajima","year":"2020","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020487","article-title":"Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors","volume":"12","author":"Castello","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-020-01539-7","article-title":"FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer","volume":"34","author":"Seban","year":"2020","journal-title":"Ann Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1186\/s12885-025-14873-8","article-title":"Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy","volume":"25","author":"Obata","year":"2025","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1530507","article-title":"Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy","volume":"14","author":"Qiao","year":"2025","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3747\/co.v17i4.567","article-title":"The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer","volume":"17","author":"Kasymjanova","year":"2010","journal-title":"Curr Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202555","article-title":"Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors","volume":"13","author":"Shrotriya","year":"2018","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030504","article-title":"Metabolic Signature of Warburg Effect in Cancer: An Effective and Obligatory Interplay between Nutrient Transporters and Catabolic\/Anabolic Pathways to Promote Tumor Growth","volume":"16","author":"Mathew","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.849040","article-title":"Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism","volume":"13","author":"Sharma","year":"2022","journal-title":"Front Genet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.104079","article-title":"Revisiting of Cancer Immunotherapy: Insight from the Dialogue between Glycolysis and PD-1\/PD-L1 Axis in the Tumor Microenvironment","volume":"21","author":"Liu","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06751-1","article-title":"Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis)","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1568755","article-title":"A PET-CT radiomics model for immunotherapy response and prognosis prediction in patients with metastatic colorectal cancer","volume":"15","author":"Chen","year":"2025","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02948-z","article-title":"Intratumoral and peritumoral PET\/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC","volume":"132","author":"Lin","year":"2025","journal-title":"Br J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91575-y","article-title":"Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images","volume":"15","author":"Lu","year":"2025","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10503-8","article-title":"[18F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study","volume":"34","author":"Yang","year":"2024","journal-title":"Eur Radiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07435-4","article-title":"Using 18F-FDG PET\/CT-derived body composition features to predict lymphovascular invasion in non-small cell lung cancer","volume":"53","author":"Jiang","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051238","article-title":"FDG uptake and prognosis in NSCLC treated with immunotherapy","volume":"12","author":"Kaira","year":"2020","journal-title":"Cancers"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1939672","article-title":"Cancer immunotherapy efficacy and patient sex","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5904","article-title":"Sex differences in response to immune checkpoint inhibitors","volume":"5","author":"Wallis","year":"2019","journal-title":"JAMA Oncol"},{"key":"B47","article-title":"TTF-1 expression and prognosis in lung adenocarcinoma","volume":"4","author":"Yatabe","year":"2009","journal-title":"J Thorac Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.05.105","article-title":"Prognostic factors of oligometastatic NSCLC","volume":"10","author":"Li","year":"2018","journal-title":"J Thorac Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non\u2013small-cell lung cancer","volume":"10","author":"Anagnostou","year":"2020","journal-title":"Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1425837","article-title":"Radiomics based on 18F-FDG PET\/CT for prediction of treatment response in non-small cell lung cancer","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1837219\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:53:55Z","timestamp":1785905635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1837219\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":53,"alternative-id":["10.3389\/fonc.2026.1837219"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1837219","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1837219"}}